The finding is notable because ABHD6 belongs to a protein family commonly associated with enzymatic activity. The “ABHD” designation refers to an alpha/beta hydrolase domain, a structural feature often found in enzymes that break down lipids or other biological molecules. Yet the research focuses on a non-enzymatic role for ABHD6 in the liver. In this context, the protein appears to act as a molecular coordinator, helping organize or influence signaling events rather than functioning primarily as a catalyst. That distinction could reshape how scientists understand the biological importance of proteins traditionally classified according to their potential enzyme domains.

The liver is central to metabolic control. It stores glucose as glycogen, produces glucose when energy levels fall, processes dietary fats and synthesizes a wide range of essential molecules. When hepatic signaling becomes dysregulated, the consequences can extend throughout the body, contributing to insulin resistance, abnormal lipid accumulation and metabolic disorders. The new work places ABHD6 within this complex regulatory network and connects it to Akt and FoxO1, two proteins that serve as important decision-makers in the liver’s response to hormones and nutrients.

Akt, also known as protein kinase B, is activated downstream of insulin and other growth-related signals. Once switched on, Akt can modify target proteins by adding phosphate groups to them, changing their location, stability or activity. One of its important targets is FoxO1, a transcription factor that controls genes involved in glucose production. Under conditions in which insulin signaling is low, FoxO1 can promote the expression of genes that help the liver generate glucose. When insulin activates Akt, FoxO1 is typically phosphorylated and redirected away from the nucleus, reducing the transcriptional program associated with glucose output.

The study’s central message is that hepatic ABHD6 interacts with this Akt–FoxO1 axis to regulate metabolic health. This suggests that ABHD6 may influence whether insulin signals are effectively transmitted to FoxO1, thereby affecting the liver’s decision to produce or store glucose. The protein could also help coordinate related metabolic programs, although the precise molecular details and the relative importance of each interaction will depend on the experimental evidence presented in the full study. By describing ABHD6 as non-enzymatic, the researchers point toward a regulatory mechanism based on protein–protein interactions, cellular localization or signaling-platform assembly.

Such mechanisms are increasingly recognized as fundamental to biology. A protein does not always need to catalyze a reaction to have a powerful effect. Some proteins function as scaffolds, bringing signaling partners into proximity. Others act as adaptors, connecting separate molecular pathways, or as sensors that respond to changes in nutrients, hormones or cellular stress. If ABHD6 performs one or more of these roles in hepatocytes, even modest changes in its abundance or location could alter the strength and timing of Akt–FoxO1 signaling. This type of regulation may help explain why proteins with apparently similar enzymatic domains can have very different physiological effects.

The work also raises questions about the relationship between ABHD6’s enzymatic identity and its regulatory function. Proteins can retain a recognizable catalytic domain while using that structure for another purpose, such as binding to membranes or interacting with signaling partners. Alternatively, a protein may possess catalytic potential in some contexts but operate mainly through non-catalytic mechanisms in a particular tissue. The liver-specific focus of the research is therefore important: ABHD6 may behave differently depending on the cell type, nutritional state or metabolic environment in which it is expressed.

From a medical perspective, the findings could open a new route for studying metabolic disease. Many existing approaches target enzymes, receptors or hormones directly. A non-enzymatic regulator such as ABHD6 would present a different therapeutic challenge, because blocking or enhancing its activity might not be sufficient; researchers may need to disrupt or stabilize specific protein interactions instead. At the same time, targeting a signaling interface could offer precision, potentially adjusting the Akt–FoxO1 pathway without broadly suppressing every function of Akt or FoxO1 throughout the body. Any such strategy would require careful testing, since these proteins also participate in growth, survival and stress responses in multiple tissues.

The discovery places hepatic ABHD6 among a growing group of molecular regulators that influence metabolism by controlling communication inside cells. It does not simply add another protein to the long list of factors linked to glucose regulation; it suggests that the architecture of signaling itself may be a crucial part of metabolic health. Future studies will need to determine exactly where ABHD6 binds within the Akt–FoxO1 pathway, how its interaction changes during fasting or nutrient excess, and whether manipulating the protein can improve metabolic dysfunction in relevant disease models. For now, the study offers a striking new perspective on how a protein that does not need to act as an enzyme can still help decide how the liver manages energy.

Subject of Research: Hepatic ABHD6 and its non-enzymatic interaction with the Akt–FoxO1 signaling axis in metabolic health

Article Title: Non-enzymatic hepatic ABHD6 interacts with Akt-FoxO1 axis to regulate metabolic health

Article References: Li, G., Maeyens, L.T., Yin, J. et al. Non-enzymatic hepatic ABHD6 interacts with Akt-FoxO1 axis to regulate metabolic health. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76237-5

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76237-5

Keywords: ABHD6, liver, hepatic metabolism, Akt, FoxO1, insulin signaling, glucose regulation, metabolic health, non-enzymatic regulation

Hepatic ischemia-reperfusion injury is an inevitable yet complex pathologic process triggered by the temporary deprivation of blood supply followed by restoration, resulting in cellular stress, inflammation, and apoptosis. For decades, clinicians and scientists alike have wrestled with the challenge of reducing IRI’s detrimental impact on hepatic function and patient outcomes. The new findings focus on the nicotinamide N-methyltransferase (NNMT) enzyme and its metabolic product, 1-methylnicotinamide (1-MNA), which have historically been studied in cancer metabolism and inflammation but whose precise role in liver injury remained obscure until now.

The authors, led by Yin, Qian, and Yu, demonstrated that enhancing NNMT activity dramatically increased the levels of 1-MNA within hepatocytes exposed to ischemic conditions. This elevation proved essential in antagonizing apoptotic pathways and supporting cellular survival during reperfusion. Mechanistically, the study revealed a cascade involving the activation of the AKT kinase, phosphorylation and nuclear exclusion of the forkhead box O1 (FOXO1) transcription factor, suppression of angiopoietin 2 (ANGPT2) expression, and subsequent modulation of the c-Jun N-terminal kinase (JNK) pathway. Together, these molecular events orchestrate a concerted defense against oxidative stress and inflammatory signaling that typically drive tissue injury.

The research team utilized state-of-the-art genetic, pharmacological, and biochemical approaches to dissect this signaling axis. Employing in vivo murine models of hepatic IRI, they administered NNMT activators and 1-MNA supplementation, observing significant reductions in serum transaminases, histological liver damage, and inflammatory cytokine levels compared to controls. Conversely, silencing NNMT gene expression amplified liver injury, underscoring the enzyme’s protective role. These results were further corroborated by in vitro experiments on primary hepatocytes and hepatic stellate cells, which confirmed the mechanistic involvement of the AKT/FOXO1/ANGPT2/JNK pathway.

One transformative aspect of this work is the elucidation of how metabolic enzymes like NNMT, traditionally regarded for their roles in cellular metabolism, intersect with critical signaling pathways governing stress responses in non-neoplastic tissues. The modulation of FOXO1, a pivotal transcription factor implicated in gluconeogenesis, cell cycle regulation, and apoptosis, points to a finely tuned balance between metabolic adaptation and cell fate decisions in ischemic liver injury. By reducing ANGPT2, a molecule known to promote vascular instability and inflammation, the study reveals a novel anti-inflammatory mechanism linked to NNMT activity.

The JNK pathway’s involvement in hepatocyte apoptosis and inflammation has been extensively studied and associated with poor outcomes in IRI; thus, the discovery that the NNMT/1-MNA axis indirectly inhibits JNK activation via upstream signaling modifications offers a promising target for therapeutic intervention. This axis represents a multi-tiered checkpoint where metabolic signals intersect with transcriptional and post-translational regulators to halt progression toward cell death.

The potential clinical implications of these discoveries are vast. Current strategies to prevent hepatic IRI largely rely on supportive care and nonspecific pharmacological agents with limited efficacy. The identification of NNMT and 1-MNA as endogenous protective factors provides a tangible target for drug development. Small molecule NNMT activators or analogs of 1-MNA could be administered perioperatively to reinforce hepatic resilience during surgical interventions, markedly improving organ viability and patient prognosis.

Furthermore, this research paves the way for personalized medicine approaches. Variations in NNMT expression or function, potentially influenced by genetic polymorphisms or comorbid conditions such as metabolic syndrome, might predispose individuals to more severe IRI. Screening for such biomarkers could guide stratification of patients and tailored prophylactic therapies, enhancing the safety of hepatic surgeries and transplantation.

Delving deeper into the molecular mechanisms, the study highlights how AKT phosphorylation acts as a molecular switch promoting hepatocyte survival. AKT’s activation leads to phosphorylation of FOXO1, excluding it from the nucleus and preventing the transcription of genes involved in oxidative stress and apoptosis. This regulatory step also diminishes the expression of ANGPT2, thereby reducing endothelial dysfunction and inflammation within the liver microenvironment. The resultant decreased activation of JNK alleviates the pro-apoptotic signaling cascade, sparing hepatic cells from irreversible damage.

The researchers underscore the importance of crosstalk between hepatocytes and vascular endothelium in the context of IRI. By modulating angiopoietin signaling, NNMT/1-MNA not only protects parenchymal cells but also stabilizes the hepatic vasculature, reducing leukocyte infiltration and microvascular occlusion. This dual action is critical for preserving liver architecture and ensuring adequate post-ischemic perfusion.

Beyond liver-specific implications, the NNMT/1-MNA axis may represent a broader paradigm in ischemia-reperfusion biology. Similar protective effects mediated by this pathway could exist in other organs susceptible to ischemia, such as the heart, kidneys, and brain. Hence, the translational potential of targeting NNMT extends beyond hepatology, inviting cross-disciplinary collaboration in developing anti-IRI therapies.

The publication also raises intriguing questions about the metabolic adaptations during ischemia and recovery. NNMT’s role in methylation and nicotinamide metabolism intersects with cellular NAD+ pools and epigenetic regulation, suggesting that enhancing NNMT activity could influence redox homeostasis and gene expression dynamics during injury. Future studies exploring these connections will expand our understanding of metabolic control in tissue repair.

In summary, Yin and colleagues have mapped a sophisticated molecular network through which NNMT and its product 1-MNA guard the liver against ischemia-reperfusion injury. By activating AKT signaling, repressing FOXO1 and ANGPT2, and attenuating JNK-mediated apoptosis, this axis orchestrates a multifaceted protective response. The translational implications are profound, offering novel strategies to mitigate one of the greatest challenges in hepatic surgery and transplantation medicine.

As the quest for effective IRI therapeutics continues, targeting endogenous metabolic-signal transduction nodes like the NNMT/1-MNA axis holds immense promise. This pioneering study marks a significant step forward in hepatic injury research, harmonizing metabolic regulation with intricate signaling pathways to discern potential therapeutic targets. With further validation and drug development, it could soon transform clinical approaches, minimizing liver damage, improving graft survival, and enhancing quality of life for patients undergoing complex hepatic procedures.

Subject of Research: The protective role of NNMT and its metabolic product 1-MNA in hepatic ischemia-reperfusion injury mediated via the AKT/FOXO1/ANGPT2/JNK signaling axis.

Article Title: NNMT/1-MNA protects against hepatic ischemia-reperfusion injury through the AKT/FOXO1/ANGPT2/JNK axis.

Article References:
Yin, B., Qian, B., Yu, H. et al. NNMT/1-MNA protects against hepatic ischemia-reperfusion injury through the AKT/FOXO1/ANGPT2/JNK axis. Nat Commun 16, 4779 (2025). https://doi.org/10.1038/s41467-025-59968-9

Image Credits: AI Generated